246 related articles for article (PubMed ID: 17607363)
1. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.
Caulin C; Nguyen T; Lang GA; Goepfert TM; Brinkley BR; Cai WW; Lozano G; Roop DR
J Clin Invest; 2007 Jul; 117(7):1893-901. PubMed ID: 17607363
[TBL] [Abstract][Full Text] [Related]
2. C/EBPβ deletion in oncogenic Ras skin tumors is a synthetic lethal event.
Messenger ZJ; Hall JR; Jima DD; House JS; Tam HW; Tokarz DA; Smart RC
Cell Death Dis; 2018 Oct; 9(11):1054. PubMed ID: 30323292
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
5. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
6. Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner.
Muñoz DM; Tung T; Agnihotri S; Singh S; Guha A; Zadeh G; Hawkins C
Glia; 2013 Nov; 61(11):1862-72. PubMed ID: 24038521
[TBL] [Abstract][Full Text] [Related]
7. Ras mutation promotes p53 activation and apoptosis of skin keratinocytes.
Zhao Y; Chaiswing L; Bakthavatchalu V; Oberley TD; St Clair DK
Carcinogenesis; 2006 Aug; 27(8):1692-8. PubMed ID: 16613839
[TBL] [Abstract][Full Text] [Related]
8. Gain of function in the mouse model of a recurrent mutation p53
Zhao L; Wang B; Zhao X; Wu X; Zhang Q; Wei C; Shi M; Li Y; Tang W; Zhang J; Yang J; Singh SK; Jia S; Luo Y
Mol Carcinog; 2018 Feb; 57(2):147-158. PubMed ID: 28949402
[TBL] [Abstract][Full Text] [Related]
9. Populations of p53 codon 270 CGT to TGT mutant cells in SKH-1 mouse skin tumors induced by simulated solar light.
Verkler TL; Delongchamp RR; Couch LH; Miller BJ; Warbritton A; Mellick PW; Howard PC; Parsons BL
Mol Carcinog; 2008 Nov; 47(11):822-34. PubMed ID: 18381587
[TBL] [Abstract][Full Text] [Related]
10. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
12. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
13. The differential effects of mutant p53 alleles on advanced murine lung cancer.
Jackson EL; Olive KP; Tuveson DA; Bronson R; Crowley D; Brown M; Jacks T
Cancer Res; 2005 Nov; 65(22):10280-8. PubMed ID: 16288016
[TBL] [Abstract][Full Text] [Related]
14. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.
Dai C; Whitesell L; Rogers AB; Lindquist S
Cell; 2007 Sep; 130(6):1005-18. PubMed ID: 17889646
[TBL] [Abstract][Full Text] [Related]
15. P53 protein and pathogenesis of melanoma and nonmelanoma skin cancer.
Benjamin CL; Melnikova VO; Ananthaswamy HN
Adv Exp Med Biol; 2008; 624():265-82. PubMed ID: 18348463
[TBL] [Abstract][Full Text] [Related]
16. The Rb family connects with the Tp53 family in skin carcinogenesis.
Lara MF; Paramio JM
Mol Carcinog; 2007 Aug; 46(8):618-23. PubMed ID: 17486638
[TBL] [Abstract][Full Text] [Related]
17. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari AS; Iwakuma T
Fukuoka Igaku Zasshi; 2009 Jun; 100(6):217-28. PubMed ID: 19670804
[TBL] [Abstract][Full Text] [Related]
19. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
20. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.
Acin S; Li Z; Mejia O; Roop DR; El-Naggar AK; Caulin C
J Pathol; 2011 Dec; 225(4):479-89. PubMed ID: 21952947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
